Literature DB >> 2501801

Flupenthixol and fluvoxamine in mild to moderate depression: a comparison in general practice.

B A Hamilton, P G Jones, A N Hoda, P M Keane, I Majid, S I Zaidi.   

Abstract

Seventy-two depressed patients attending general practices were randomly allocated to treatment with either flupenthixol dihydrochloride (1 to 2 mg/day) or fluvoxamine maleate (100 to 200 mg/day) to assess efficacy and side-effects over a 4-week period. Clinical assessments were carried out before medication (Day 1) and on Days 8, 15 and 29 of treatment using the Hamilton Rating Scale for Depression, Clinical Global Impressions (CGI) and a patient self-assessment visual analogue scale for depression. Unwanted symptoms were also recorded. Reduction in mean total scores on the Hamilton scale at each assessment and therapeutic effect improvement on the CGI were greater for patients treated with flupenthixol (p less than 0.05). Reduction in unwanted symptoms was progressive in both groups, but more pronounced in patients receiving flupenthixol. Twice as many new symptoms arose in the fluvoxamine group compared to the flupenthixol group. Four patients were withdrawn in the fluvoxamine group due to untoward drug effects compared with none in the flupenthixol group.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501801

Source DB:  PubMed          Journal:  Pharmatherapeutica        ISSN: 0308-051X


  3 in total

1.  The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol.

Authors:  S Kutcher; G Papatheodorou; S Reiter; D Gardner
Journal:  J Psychiatry Neurosci       Date:  1995-03       Impact factor: 6.186

Review 2.  A comparison of active drugs for the treatment of dysthymia.

Authors:  M Silva de Lima; M Hotopf
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 3.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.